San Francisco Bay Area biotech stories.
Tuesday, July 24, 2012
Medivation nets $10 million as prostate cancer drug moves toward approval
Medivation Inc. landed $10 million from partner
Astellas Pharma Inc.
after the Food and Drug Administration said the San Francisco drug developer's late-stage experimental prostate cancer treatment will get a priority review.
The milestone payment to San Francisco-based Medivation (NASDAQ: MDVN) is based on the FDA's acceptance of the company's new drug application, Medivation said Tuesday.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)